Campath update

A board to discuss the soon-to-be released drug Campath as a treatment for Multiple Sclerosis

Campath update

Postby dignan » Wed Feb 15, 2006 9:23 am

From Genzyme's financial results yesterday...

Genzyme and Schering AG Germany await comments from the FDA, following which they hope to resume dosing soon in the Phase 2 clinical trial evaluating Campath for the treatment of multiple sclerosis. The companies submitted a risk-management plan to the FDA and the EMEA earlier this month, which was approved by the study's Data Safety Monitoring Board. Results from a pre-planned interim analysis of the Phase 2 trial were highly encouraging, and the companies are working with participating clinical investigators and regulatory authorities to ensure that a comprehensive program is in place to manage patient safety in both the ongoing Phase 2 and planned Phase 3 studies.

Genzyme will request a meeting with the FDA during the first half of this year to review the proposed protocol for the Phase 3 study, which is now expected to begin during the second half of this year. Additional interim data from the Phase 2 study is expected to be available this year. ... ID=5508707
User avatar
Family Elder
Posts: 1608
Joined: Wed Aug 11, 2004 3:00 pm


Return to Campath (Lemtrada, Alemtuzumab)


  • Related topics
    Last post

Who is online

Users browsing this forum: No registered users

Contact us | Terms of Service